At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
LBL-007 Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies
In Brief
A Phase 2 clinical trial evaluating LBL-007 Injection and Toripalimab Injection for Advanced Malignant Tumors. Completed, enrolled 80 participants across 14 sites.
Detailed Summary
This is a single-arm, open-label, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, PK characteristics, immunogenicity and efficacy of LBL-007 in combination with Toripalimab in Treatment of Advanced Malignant Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Tumors
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartNov 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedNov 1, 2021
Enrollment StartNov 30, 2021
Primary CompletionMay 22, 2024
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 4.7 years ago
Interventions
LBL-007 Injectiondrug
LBL-007 Injection; dose A or dose B; Q3W
Toripalimab Injectiondrug
Toripalimab Injection; dose C; Q3W